Immunic to highlight vidofludimus calcium's potential as MS therapy at upcoming forumProactive Investors • 02/26/25
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple SclerosisPRNewsWire • 02/26/25
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical TestingPRNewsWire • 02/20/25
Immunic eyes transformative year ahead for MS therapy vidofludimus calcium - ICYMIProactive Investors • 01/11/25
Immunic's IMU-856 shows potential in gastrointestinal health trials - ICYMIProactive Investors • 11/16/24
Immunic reports positive Phase 1 results for celiac disease therapy published in The LancetProactive Investors • 11/13/24
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & HepatologyPRNewsWire • 11/13/24
Immunic highlights progress in multiple sclerosis programs, targets 2025 milestonesProactive Investors • 11/07/24
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatePRNewsWire • 11/07/24
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate UpdatePRNewsWire • 10/31/24
Immunic to Participate in Industry, Scientific and Investor Conferences in NovemberPRNewsWire • 10/29/24
Immunic Phase 3 MS study advances following positive recommendation from independent committeeProactive Investors • 10/22/24
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple SclerosisPRNewsWire • 10/22/24
Immunic highlights lead asset's promise in multiple sclerosis at ECTRIMS CongressProactive Investors • 09/18/24
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple SclerosisPRNewsWire • 09/18/24